Xencor, Inc. (XNCR): Price and Financial Metrics


Xencor, Inc. (XNCR): $22.58

0.35 (+1.57%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add XNCR to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

XNCR POWR Grades


  • XNCR scores best on the Sentiment dimension, with a Sentiment rank ahead of 74.69% of US stocks.
  • XNCR's strongest trending metric is Stability; it's been moving down over the last 179 days.
  • XNCR's current lowest rank is in the Momentum metric (where it is better than 8.18% of US stocks).

XNCR Stock Summary

  • Of note is the ratio of Xencor Inc's sales and general administrative expense to its total operating expenses; merely 6.52% of US stocks have a lower such ratio.
  • With a year-over-year growth in debt of 192.13%, Xencor Inc's debt growth rate surpasses 94.24% of about US stocks.
  • Revenue growth over the past 12 months for Xencor Inc comes in at 124.23%, a number that bests 93.29% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Xencor Inc, a group of peers worth examining would be RCUS, INBX, ATRA, MRTX, and ARCT.
  • Visit XNCR's SEC page to see the company's official filings. To visit the company's web site, go to www.xencor.com.

XNCR Valuation Summary

  • XNCR's EV/EBIT ratio is 79.3; this is 170.65% higher than that of the median Healthcare stock.
  • XNCR's EV/EBIT ratio has moved up 83.4 over the prior 94 months.
  • Over the past 94 months, XNCR's EV/EBIT ratio has gone up 83.4.

Below are key valuation metrics over time for XNCR.

Stock Date P/S P/B P/E EV/EBIT
XNCR 2021-08-31 11.1 3.1 84.0 79.3
XNCR 2021-08-30 11.1 3.1 84.1 79.4
XNCR 2021-08-27 10.8 3.0 82.2 77.5
XNCR 2021-08-26 10.4 2.9 79.4 74.6
XNCR 2021-08-25 10.6 2.9 80.8 76.1
XNCR 2021-08-24 10.5 2.9 79.4 74.7

XNCR Growth Metrics

    The 3 year net income to common stockholders growth rate now stands at 323%.
  • The 2 year revenue growth rate now stands at 145.92%.
  • Its 2 year cash and equivalents growth rate is now at -70.66%.
XNCR's revenue has moved up $241,588,000 over the prior 70 months.

The table below shows XNCR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 275.111 -16.853 82.631
2021-09-30 162.949 -61.559 -4.121
2021-06-30 178.632 -26.402 23.52
2021-03-31 124.274 -44.43 -63.746
2020-12-31 122.694 -5.004 -69.333
2020-09-30 84.356 -41.665 -82.554

XNCR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • XNCR has a Quality Grade of D, ranking ahead of 9.2% of graded US stocks.
  • XNCR's asset turnover comes in at 0.261 -- ranking 167th of 682 Pharmaceutical Products stocks.
  • PTGX, MDWD, and ALBO are the stocks whose asset turnover ratios are most correlated with XNCR.

The table below shows XNCR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.261 1 0.051
2021-03-31 0.185 1 -0.142
2020-12-31 0.184 1 -0.145
2020-09-30 0.128 1 -0.162
2020-06-30 0.106 1 -0.154
2020-03-31 0.114 1 -0.111

XNCR Price Target

For more insight on analysts targets of XNCR, see our XNCR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $53.55 Average Broker Recommendation 1.41 (Moderate Buy)

XNCR Stock Price Chart Interactive Chart >

Price chart for XNCR

XNCR Price/Volume Stats

Current price $22.58 52-week high $43.61
Prev. close $22.23 52-week low $21.98
Day low $22.05 Volume 107,874
Day high $22.90 Avg. volume 336,812
50-day MA $26.13 Dividend yield N/A
200-day MA $32.90 Market Cap 1.34B

Xencor, Inc. (XNCR) Company Bio


Xencor Inc. is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases and cancer. The company was founded in 1997 and is based in Monrovia, California.


XNCR Latest News Stream


Event/Time News Detail
Loading, please wait...

XNCR Latest Social Stream


Loading social stream, please wait...

View Full XNCR Social Stream

Latest XNCR News From Around the Web

Below are the latest news stories about Xencor Inc that investors may wish to consider to help them evaluate XNCR as an investment opportunity.

Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q4 2021 Results - Earnings Call Transcript

Xencor, Inc. (XNCR) Q4 2021 Earnings Conference Call February 22, 2022, 17:00 ET Company Participants Charles Liles - Associate Director and Head, Corporate Communications & IR Bassil Dahiyat - Co-Founder, CEO, President & Director Allen Yang - SVP & Chief Medical Officer John Kuch - SVP & CFO John Desjarlais...

SA Transcripts on Seeking Alpha | February 24, 2022

Xencor GAAP EPS of $1.21 beats by $1.11, revenue of $154.02M beats by $77.73M

Xencor press release (XNCR): Q4 GAAP EPS of $1.21 beats by $1.11.Revenue of $154.02M (+268.0% Y/Y) beats by $77.73M.The company expects to have cash to fund research and…

Seeking Alpha | February 23, 2022

Xencor Reports Fourth Quarter and Full Year 2021 Financial Results

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a review of recent business and clinical highlights. “In 2021, we made significant decisions to advance our portfolio of internal XmAb® drug candidates — the initiation of Phase 2 trials

Business Wire | February 23, 2022

Xencor (XNCR) Q4 Earnings and Revenues Beat Estimates

Xencor (XNCR) delivered earnings and revenue surprises of 157.45% and 42.10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 23, 2022

Shareholders in Xencor (NASDAQ:XNCR) have lost 35%, as stock drops 4.0% this past week

The simplest way to benefit from a rising market is to buy an index fund. While individual stocks can be big winners...

Yahoo | February 22, 2022

Read More 'XNCR' Stories Here

XNCR Price Returns

1-mo -13.15%
3-mo -28.59%
6-mo -36.29%
1-year -42.46%
3-year -31.24%
5-year 6.76%
YTD -43.72%
2021 -8.04%
2020 26.87%
2019 -4.89%
2018 64.96%
2017 -16.72%

Continue Researching XNCR

Want to see what other sources are saying about Xencor Inc's financials and stock price? Try the links below:

Xencor Inc (XNCR) Stock Price | Nasdaq
Xencor Inc (XNCR) Stock Quote, History and News - Yahoo Finance
Xencor Inc (XNCR) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7322 seconds.